Introduction
The first-line treatment of breast cancer is usually relied on surgery and radiotherapy, and is frequently supplemented by adjuvant chemo-or hormonotherapies. Unfortunately, breast cancer is highly resistant to chemotherapy, It has an urgent need in developing novel anticancer agents presenting low cytotoxic side-effects, but effective inhibit tumor cell proliferation pathway [1, 2] .
Curcumin, a phenolic compound extract from rhizome of the plant Curcuma longa is found to have inhibitory effects towards a board range of tumors. In breast cancer, curcumin's anticancer effect has been anticipated in relating to induce apoptosis at G2 phase of cell cycle via a p53-dependent pathway [3] , but it's role in G1/S transition of breast cancer has not been established well. Based on the evolving understanding of molecular basis of breast cancer, it has been explained that pathways activated by NFκB up-regulation are implicated not only in cell proliferation including cyclin D1 [4] but also regulate promoters that encode several MMPs.
Therefore, in this study, we attempt to investigate the cell inhibition activity of curcumin on the NFκB and its regulatory genes including G1 cyclins and MMPs in BT-438 breast cancer cells and MDA-MB-231 breast cancer cells. Estrogen Receptor (ER) positive breast cancers are often beneficial from anti-hormonal drugs on either inhibiting interaction of oestradiol with ER or interrupting oestradiol synthesis. However, ER negative breast cancer, being lack of functional estrogen receptor, cannot be targeted by these therapies and are more aggressive with poorer prognoses [5] . In our study, we used the MDA-MB-231 and BT-483 human breast cancer cell line as the model of ER-negative and ER-positive breast cancers respectively in comparing.
Materials and Methods
Curcumin(Molecular Weight 368.38) purchased from Sigma Chemicals (St. Louis, MO) was accurately weighed and dissolved in dimethyl sulphoxide (DMSO) (Sigma, St. Louis, MO) to a concentration of 500μg/mL as a stock solution. It was diluted (50μg/mL) in DMEM and Leibovitz's L-15 supplemented with fetal bovine serum (10%) (Invitrogen, Carlsbad, California, US) respectively. The dilution (50μg/mL) was further diluted with supplemented medium to a series of concentrations.
Both of ER-positive breast cancer cell line BT-483 and ER-negative breast cancer cell line MDA-MB-231 were bought from the American Type Culture Collection (Rockville, MD, USA).
BT-483 were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with fetal bovine serum (10%), l-glutamine (2 mM) and antibiotics (penicillin100 units/ml; streptomycin 100 mg/ml) at 37°C in an atmosphere of 5% CO 2, while MDA-MB-231 cells were grown in Leibovitz's L-15 medium with 2 mM L-glutamine, supplemented with fetal bovine serum (10%), l-glutamine (2mM) and antibiotics (penicillin100 units/ml; streptomycin 100 mg/ml) at 37°C without CO 2. Cells were cultured at a density of 5 × 10 3 cells/well into 96-well plates. Cell growth was followed for 24 and 48 hr after stimulation in the presence or absence of curcumin (1, 1.25, 2.5, 5, 10, 20 μg/mL, namely 2.7, 4.1, 6.8, 13.6, 27, 54μM,). Medium alone was a negative control. Cell proliferation was assessed in vitro using the water soluble tetrazolium WST-1 (Roche, Indianapolis, IN).
Human breast cancer lines MDA-MB-231 and BT-483 were cultured with curcumin at the concentration of 2.5 μg/mL and 5μg/mL respectively for 48 hours in standard humidified incubator. Total RNA was extracted by Geneaid® RNA Mini Kit (cultured cells) (Geneaid, Taiwan) according to the manufacture's instructions. The mRNA levels of the MMPs were determined by RT-PCR. Primer sequences for MMP-1, 3, 9 were previous described [6] . The relative target mRNA expression level was normalized by β-actin (forward 5'-CCTCTATGCCAACACAGTGC-3' reverse 5'-ATACTCCTGCTTGCTGATCC -3') in the same sample. PCR products were electrophoretic displayed on a 2% agrose gel with ethidium bromide staining and captured in gel documentation system (Bio-Rad, Hercules, CA, USA).
Nuclear proteins were extracted from cultured cells as well. Protein concentrations were determined by using the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Sample proteins were resolved by 10% sodium dodecylsulfate polyacrylamide gel electrophoresis and then electrophoretically transferred to nitrocellulose. The primary antibody of NFκB were added and incubated at 4˚C overnight. Then membranes were incubated with corresponding secondary antibodies for 1 hour. Protein bands were revealed by the ECL PLUS kit (GE. Healthcare
Bio-Sciences, NJ, USA). The amount of NFκB protein was corrected by the signal of β-actin in the same sample. Quantification was achieved by quantifying the densities of the bands with the program of Quantity One.
The immunocytochemical studies for both cell lines were performed culturing in 24-well plate with glass-cover slides at a density of 10 5 cells/well for 24 hours. The application of curcumin (5μg/mL) was followed by 48 hours incubation. The cells were fixed and immunostained with the following antibodies: Cyclin D1, p21, CDK4 and NFκB. Staining was performed using 2% DAB substrate-chromogen solution. The intensity of DAB staining was examined under a standard light microscope using × 40 magnification.
Statistical analysis was performed using SPSS 16.0 (SPAA Inc, Chicago, IL, USA) including the ANOVA test for pairwise comparisons. The continuous variables were analyzed by independentsample t test. All P values reported were two-sided with P < 0.05 considered significant.
Experimental results were presented as the mean ± SD.
Results and Disscussion: Effects of curcumin on breast cancer cell proliferation
Treatment of breast cancer cell BT-483 and MDA-MB-231 with curcumin exhibited inhibitory effect on cell growth (Figure 1) . Curcumin with the dose as low as 1.25µg/ml was found to be effective on BT-483 and treatment with 5µg/ml for 48 h could result in a 60-70% inhibition.
Curcumin with the dose as low as 2.5µg/ml was quite effective on MDA-MB-231 and treatment with 5µg/ml for 48 h resulted in a 50-60% inhibition. Thus we selected 5μg/mL concentration of curcumin as the optimal concentration for the subsequent experiments. MDA-MB-231 were incubated with curcumin at the 5μg/mL (Fig 3. 1 B, D, F) and without curcumin ( Fig 3. 1 A, C, E) for 48 hours. The intensity of DAB staining was examined under a light microscope on × 40 magnification. The intensity of the stain was assessed by their thickness and darkness of the DAB precipitate.
BT-483 were incubated with curcumin at the concentration of 5μg/mL ( Fig 3. 2 B, D, F) or without curcumin ( Fig 3. 2 A, C, E) for 48 hours. The intensity of DAB staining was examined under a light microscope with × 40 magnification. The intensity of the stain was assessed by their thickness and darkness of the DAB precipitate.
Effect of curcumin on NFκB protein of MDA-MB231 and BT-483 breast cancer cells.
To investigate whether curcumin inhibit NF-κB in BT-483 and MDA-MB-231 human breast cancer, we perform immunostaining and western blot of NF-κB p65 protein. As shown in Fig. 5 .
Treatment of BT-483 and MDA-MB-231 cell lines with curcumin at the concentration of 5μg/mL for 12, 24, 48 hours respectively shown a reduced expression of nuclear NF-κB. Proteins termed CDK inhibitory proteins including INK4 proteins and the Kip/Cip proteins can also bind to cyclin-Cdk complexes. Kip/Cip proteins, comprised of p27, p21, and p57, can inhibit each of the cyclin-CDK complexes being essential for G1 progression and S phase entry [12] . p21 cip1/waf1 is known to inhibit the kinase activity of the CDK4-Cyclin D1. Inhibition by p27 is another generally proposed mechanism to explain the inactivity of D-type cyclin-CDK4
complexes [12] . p27 concentration allows the nuclear import and activation of cyclin D3-CDK4
complexes [13] . We investigated curcumin's regulatory effect on p21 MDA-MB-231 and BT-483 while having no effect on the MMP-3, 9.
Constantly activated NF-κB directly induce genes that promote cell proliferation including cyclin D1 and the cyclin-dependent kinase inhibitors p21 [4] . The transcription factor NFκB has also been shown to be critically involved in the regulation of MMP-1, MMP-3 [15] . Curcumin has been reported to have a synergistic effect against the growth of both ER-positive and ER-negative cells [14] . We proposed that curcumin may suppress NF-κB which in turn suppressing MMPs, cyclin D1. Under the normal conditions, NF-κB as an inactive heterotrimer present in the cytoplasm. Cytokines such as TNF-α and environmental hazards like ionizing radiation or toxins trigger the translocation of NF-κB from the cytoplasm to the nucleus.
Activation of this transcription factor protects a variety of cell types from the damage that induced by pro-apoptotic stimuli [16] . It is therefore, inhibition of NF-κB activity is not only desirable in the treatment of inflammation but also in cancer therapy. Curcumin decreased nuclear and cytoplasmic p65 immunopositivity of both BT-483 and MDA-MB-231 cells.
Curcumin inhibited intranuclear expression of NF-κB p65 in MDA-MB-231 and BT-483 cells were also confirmed by western blot.
Breast cancer often progresses from the estrogen-dependent, nonmetastatic phenotype to the estrogen-independent, metastatic phenotypes. This progression is usually accompanied by altered function of the estrogen receptor or outgrowth of ER-negative cancer cells with generally high constitutive activity of NF-κB [17] . Although many estrogen receptor-positive breast cancers initially respond to antihormones drugs, responses are commonly incomplete when resistance ultimately emerging. Preclinical studies suggest that treatment strategies designed to prevent or interrupt activation of NF-κB in cell-line models of ER-positive breast cancers can restore their sensitivity to such standard endocrine agents as tamoxifen. On the other hand, activated ER can inhibit both NF-κB activation and the ability of NF-κB to regulate gene expression [18] . Further studies are necessary to investigagte how curcumin suppress the activation of NF-κB via inhibition of osteoclastogenesis in ER-positive breast cancer cell. Conceivably, our results show that curcumin can treat both ER-negative breast cancer (with generally high constitutive activity of NF-κB) and perhaps hormone-resistant ER-positive breast cancer via inhibiting the activation of NF-κB.
In summary, our finding extrapolates the antitumor activity of curcumin in mediating the breast cancer cell proliferative rate and invasion by down-regulating the NF-κB B inducing genes. Our findings suggest curcumin could be a potentially therapeutic agent for both ER-positive and ER-negative breast cancer.
